Navigation Links
Researcher Investigates Disparities in Doctor-Patient Information Exchange During Clinical Trial Offers
Date:11/29/2007

ATLANTA, Nov. 29 /PRNewswire-USNewswire/ -- Recent research from the Barbara Ann Karmanos Cancer Institute in Detroit, MI, suggests black cancer patients are less likely than white cancer patients to bring a companion with them to physician appointments, leading to possible racial disparities in informed decision-making about cancer treatment and participation in clinical trials.

This research further examines cancer patient question-asking and the role of companions during physician visits. In the past, it has been shown that patients who bring a companion with them to physician visits receive more information than those who don't.

Susan Eggly, Ph.D., assistant professor of internal medicine and member of the Communication and Behavioral Oncology program at Karmanos, presented the findings at the American Association for Cancer Research's The Science of Cancer Health Disparities conference this week in Atlanta, GA.

Nationally, clinical trials accrue disproportionately low rates of minority patients. Dr. Eggly and researchers at Karmanos believe the low rate of accrual may partially be influenced by physician-patient communication during the clinical interactions in which trials are offered.

The study showed that black and white patients both asked more questions during visits to the doctor that included an offer of a clinical trial than visits that included only standard treatment options. However, in both types of visits, black patients asked fewer questions and less frequently had a companion present to assist them in asking questions. Because increased questioning has been associated with positive patient outcomes, these findings may reveal some causes of racial health disparities, especially with regard to how much information patients get about treatment and other options for care.

"Our program is particularly interested in the way patients and companions ask questions because question-asking is associated wi
'/>"/>

SOURCE Barbara Ann Karmanos Cancer Institute
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL, Carrier of Good Cholesterol
2. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
3. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
4. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
5. K-State Researchers Bringing Expertise to Kansas City Symposium on Disease and National Security
6. U. of Md. Researchers to Develop Devices to Revolutionize Drug Research
7. 454 Sequencing(TM) in Science Today: Researchers Uncover a Genetic Basis for Different Social Behaviors in Wasps
8. Researchers Report First Successful Treatment of Chronic Traumatic Brain Injury
9. Potential Breakthrough Cancer Treatment Emerges from MIPS-Funded Clinical Trial Teaming CSA Medical Inc. and University of Maryland Researchers
10. Researchers Develop New Procedure to Screen All 46 Human Chromosomes to Identify Abnormalities in Embryos
11. Honor Society of Nursing Recognizes Researcher of HIV Risk Prevention for Poor and Underserved
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)... BILLERICA, Mass., Dec. 4 Axsun Technologies, Inc., a ... today announced the initial development and successful testing of ... Axsun believes this proprietary optical engine design raises ... of laser-based designs for swept source OCT light sources. ...
(Date:12/4/2009)... Dec. 4 Watson Pharmaceuticals, Inc. (NYSE: ... confirmed that its subsidiary, Watson Laboratories, Inc.-Florida, filed an ... and Drug Administration seeking approval to market its 8mg ... owned by Takeda Pharmaceutical Company Limited. Watson,s 8mg ...
(Date:12/4/2009)... Neal Shore and E. David Crawford presented results for ... secondary end points of biochemical recurrence rate in a ... injection) or monthly leuprolide in prostate cancer patients during ... who received FIRMAGON 240/80 mg/month had a recurrence rate ...
Breaking Medicine Technology:Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 2Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 3Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 4Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 5Watson Files FDA Application for Generic Rozerem(R) 2Watson Files FDA Application for Generic Rozerem(R) 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4Milestone Scientific Announces Notice of Allowance From US Patent and Trademark Office 55116 1Milestone Scientific Announces Notice of Allowance From US Patent and Trademark Office 55116 2Milestone Scientific Announces Notice of Allowance From US Patent and Trademark Office 55116 3School Nurses Tackle Low Parental Awareness of Meningitis Via Comprehensive National Public Education Campaign 55114 1School Nurses Tackle Low Parental Awareness of Meningitis Via Comprehensive National Public Education Campaign 55114 2School Nurses Tackle Low Parental Awareness of Meningitis Via Comprehensive National Public Education Campaign 55114 3School Nurses Tackle Low Parental Awareness of Meningitis Via Comprehensive National Public Education Campaign 55114 4Portola Pharmaceuticals Announces Two Oral Presentations on Elinogrel at European Society of Cardiology Congress 2009 13658 1Portola Pharmaceuticals Announces Two Oral Presentations on Elinogrel at European Society of Cardiology Congress 2009 13658 2
... CR011-vcMMAE for ... melanoma -, - Preliminary Phase I/II results to be presented in June ... ... CRGN ), a clinical-stage biopharmaceutical company,focused on oncology, announced today that it has ...
... ORENCIA is a First-in-Class Biologic Treatment Option Now Available for ... Use in Pediatric Patients with JIA(1,2) ... (NYSE: BMY ) today announced that the U.S. Food ... symptoms in pediatric patients six years and older with moderately ...
Other Medicine Technology:CuraGen Advances CR011-vcMMAE into Phase II 2CuraGen Advances CR011-vcMMAE into Phase II 3CuraGen Advances CR011-vcMMAE into Phase II 4U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 2U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 3U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 4U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 5U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 6U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 7U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 8U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 9U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 10
(Date:12/7/2009)... selected a Texas Wind Integration project team including Drummond Group ... smart grid demonstration project. Drummond Group,s role is overseeing the ... with strong support from the project stakeholders. , ... ... -- The Department of Energy has selected a ...
(Date:12/7/2009)... Content throughout the Clinical Workflow , ... ... Institutions currently using point-of-care resources from EBSCO Publishing ... benefit from a new agreement which gives healthcare providers ... retrieval of relevant and current information and improved quality ...
(Date:12/7/2009)... , ... Phoenix, AZ (PRWEB) December 7, 2009 -- ... spinal cord injury: The online retailer of medical supplies ... , ,Cure Medical is a forward-thinking manufacturer of catheters. In ... the company donates 10 percent of all of their pre-tax profits ...
(Date:12/7/2009)... agency A.R.M. Solutions was recognized as a leader in the ... award-winning recovery service outperforms traditional collection agencies in speed, cost, ... ... December 7, 2009 -- A.R.M. Solutions, a leading provider of ... Places to Work in Collections by insideARM.com. This is the ...
(Date:12/7/2009)... Cell Therapeutics, Inc. ("CTI") (Nasdaq and ... of St. George,s Hospital, University of London during ... Hematology ("ASH") Annual Meeting updated results from the ... of pixantrone (the "PIX 301 EXTEND trial") in ... patients who have failed 2 or more prior ...
Breaking Medicine News(10 mins):Health News:Drummond Group Awarded DOE Funds for Texas Wind Integration Project 2Health News:Drummond Group Awarded DOE Funds for Texas Wind Integration Project 3Health News:Drummond Group Awarded DOE Funds for Texas Wind Integration Project 4Health News:EBSCO Publishing and Zynx Health Expand Partnership for Integrated Access to Evidence-Based Content 2Health News:EBSCO Publishing and Zynx Health Expand Partnership for Integrated Access to Evidence-Based Content 3Health News:Online Medical Supply Superstore Adds Cure Catheters to Product Mix 2Health News:Collection Agency Named One of 2009 Best Places to Work 2Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 2Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 3Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 4Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 5
... N.J., March 23 Siemens Financial Services, Inc. ... in tax-exempt financing to El Camino Hospital in ... used to acquire a variety of Siemens Medical ... new El Camino hospital under construction.(Logo: http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO ...
... Krapf of Bear, DE, will travel to Washington, ... to meet with congressional leaders and gain their support ... a cure for epilepsy.Krapf, 13, is one of 37 ... Kids Speak Up! , a national program coordinated by ...
... COLUMBIA, S.C., March 23 /PRNewswire-USNewswire/ -- BlueCross ... state to participate in the third annual National Walk ... nationwide will encourage their employees to take part in ... workers to take time regularly during their lunch breaks ...
... Money and Improves Health With Advanced but Affordable ... money and save your health in these tough ... part medical detective as well as a skilled ... (Photo: http://www.newscom.com/cgi-bin/prnh/20090323/NY86411-b ) , (Photo: ...
... that a disturbing number of children ,wag, breakfast claiming there ... ,can,t be bothered, having a meal before going to school. ... their children skip breakfast on three to five school days ... one or two school days. , The remaining 58% of ...
... of Liverpool have demonstrated how a single-celled organism, living ... Salmonella transmission to animals and humans. , ... contaminate almost any food type, causing diarrhoea, abdominal pain ... which can also cause typhoid fever has ...
Other Medicine News:Health News:Siemens Financial Services, Inc. Announces Completion of Tax-Exempt Financing With El Camino Hospital 2Health News:Siemens Financial Services, Inc. Announces Completion of Tax-Exempt Financing With El Camino Hospital 3Health News:Delaware Youth Shares Epilepsy Message on Capitol Hill 2Health News:S.C. BlueCross Issues National Walk at Lunch Day Challenge to Employers 2Health News:Saving Money While Protecting Your Health in Tough Economic Times 2Health News:Saving Money While Protecting Your Health in Tough Economic Times 3Health News:School kids 'wagging' breakfast are missing healthy brain fuel 2Health News:Study shows how Salmonella survives in environment 2
For the qualitative detection of antibodies to HIV-1 and HIV-2 in human serum, plasma and whole blood specimens...
For the qualitative detection of antibodies to HIV-1 and HIV-2 in human serum, plasma and whole blood specimens...
... HumaPen MEMOIR is the first and only insulin pen ... and amount of your last 16 doses (including priming ... insulin you last took. With HumaPen MEMOIR, you simply ... one-unit increments (up to 60 units) after initial set-up. ...
PulmoLife is a new COPD screening device, designed for quick and easy screening of adult smokers for early detection of COPD....
Medicine Products: